21 CFR Part 11 Compliance Checklist for APAC Pharma Companies: A Practical 2026 Guide

Apr 22, 2026

If you have ever sat across the table from an FDA inspector, or even just imagined doing so, you already know that 21 CFR Part 11 is the regulation that quietly decides whether your electronic systems pass or fail.

And here in APAC, that conversation is happening more often than people realise. Pharma, biotech, and medical device companies across Singapore, Malaysia, India, Japan, Korea, and Australia are exporting to the US, partnering with American sponsors, or supplying global supply chains. Which means even if your local regulator doesnt explicitly require Part 11, your customer almost certainly does.

The trouble is, Part 11 has a reputation for being intimidating. Long. Technical. Lawyer-y. Most teams know they need to comply, but theyre not entirely sure what "compliant" actually looks like in practice.

So at Valina Services, we put together a practical, no-fluff checklist of what APAC companies actually need to have in place. No legalese. No filler. Just the things inspectors check, and the things your systems need to do.

First, the Quick Refresher: What Is 21 CFR Part 11?

21 CFR Part 11 is the FDAs regulation governing electronic records and electronic signatures. In plain English: if youre using a computer system to create, store, or sign off on records that the FDA cares about, those electronic records need to be just as trustworthy as paper ones.

It applies to any system that touches FDA-regulated activities. That includes:

Manufacturing execution systems (MES)

Laboratory information management systems (LIMS)

Electronic Quality Management Systems (eQMS)

Pharmacovigilance and drug safety platforms

Clinical trial management systems (CTMS)

Electronic batch records, electronic logbooks, electronic SOPs

If FDA regulations require you to keep a record, and you keep it electronically, Part 11 applies.

Why APAC Companies Need to Care (Even If You Dont Sell to the US Yet)

Heres the part many APAC companies miss. Part 11 isnt just an FDA problem.

Global sponsors expect it. If a US or EU pharma company outsources work to your APAC site, your systems will be audited against Part 11, whether you sell to the FDA directly or not.

Local regulators are converging. HSA, TGA, PMDA, NMPA, and CDSCO have all moved closer to global standards on data integrity and electronic records. Annex 11 in the EU and Part 11 in the US are functionally cousins, and APAC guidance increasingly mirrors both.

Audit-readiness is a competitive advantage. When a multinational is choosing between three contract manufacturers in Asia, the one thats already Part 11 compliant wins.

In other words, building Part 11 readiness now isnt just risk management. Its market access.

The Practical 21 CFR Part 11 Checklist

Heres what every APAC pharma, biotech, or medical device company should be able to tick off. Weve grouped it into the four areas inspectors actually focus on.

1. System Validation

Validation is the foundation. If your system isnt validated, nothing else really matters.

 Every GxP-relevant electronic system is documented and inventoried

 Each system has a documented validation strategy (URS, FS, DS, IQ, OQ, PQ as applicable)

 Validation is risk-based and aligned with GAMP 5

 Revalidation is triggered by changes, upgrades, or patches, not done "when we get around to it"

 Vendor documentation is reviewed, and your own testing fills the gaps

 Validation evidence is stored in a way thats easy to retrieve during an inspection

2. Audit Trails

This is the single most cited deficiency in Part 11 warning letters. If you only fix one thing this quarter, fix this.

 All GxP-relevant systems generate automatic, time-stamped audit trails

 Audit trails capture who did what, when, and why (where applicable)

 Audit trails cannot be turned off or edited by users

 Audit trails are reviewed regularly, not just before an audit

 Audit trail review is documented and forms part of your batch or case release process

 Time stamps are reliable, and time zone handling is documented

3. Electronic Signatures

If your team is clicking "Approve" on an electronic record, Part 11 has opinions about how that works.

 Each user has a unique ID and password (no shared logins, ever)

 Signatures include the printed name of the signer, the date and time, and the meaning of the signature (e.g. "Approved", "Reviewed")

 Non-biometric signatures require at least two identification components

 Password policies enforce expiry, complexity, and lock-out after failed attempts

 Theres a written policy that holds individuals accountable for actions taken under their electronic signature

 The link between the signature and the record cannot be broken

4. Access, Security, and Records

This is where "boring" controls actually save you during an inspection.

 Access is role-based and follows least-privilege principles

 User access is reviewed periodically (typically every 6 to 12 months)

 Leavers and movers are de-provisioned promptly

 Electronic records can be retrieved and produced in human-readable form on demand

 Records are retained for the full required period (and backups are tested, not just scheduled)

 Data integrity controls follow ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available

If you can confidently tick every box above, youre in genuinely good shape. If you cant, thats the gap.

The Common Pitfalls We See in APAC

After years of working with life sciences companies across the region, the same handful of issues come up again and again:

"Its validated because the vendor said so." Vendor validation is a starting point, not an end point. You still need to validate the system in your environment for your processes.

Audit trails that exist but nobody reads. An audit trail you never review is a liability waiting to happen. Inspectors will ask for evidence of review.

Shared logins for "convenience." This is the fastest way to fail a Part 11 audit. There is no acceptable justification for shared accounts on a GxP system.

Legacy systems with no upgrade path. Old systems running on unsupported platforms are a growing risk, especially as cyber requirements tighten.

Documentation that doesnt match reality. SOPs say one thing, the system does another, and the team does a third. Inspectors notice this immediately.

The good news is, all of these are fixable. The earlier you find them, the cheaper they are to fix

.

How Valina Helps APAC Companies Get Part 11 Ready

This is where we come in. At Valina Services, Part 11 readiness is part of our daily bread. We help APAC pharma, biotech, and medical device companies in three ways:

Part 11 gap assessments. 

We come in, look at your systems, your processes, and your documentation, and tell you exactly where the gaps are. No jargon, no scaring you into buying more than you need.

End-to-end Computer System Validation (CSV). Whether youre implementing a new eQMS, LIMS, or pharmacovigilance platform like SafetyEasy®, we handle the full validation lifecycle from URS to PQ, aligned with GAMP 5 and ready for inspection.

Ongoing compliance through our Compliance as a Service (CaaS) model. For companies that dont want to build a full in-house validation and compliance team, we run it for you. Validated platforms, managed processes, audit-ready documentation, all delivered as a service.

The goal is simple. We want your electronic systems to be the easiest part of your next inspection, not the part that keeps you up at night.

Final Thoughts

21 CFR Part 11 isnt going away. If anything, the bar is rising. Cyber threats are sharper, regulators are paying more attention to electronic records, and global supply chains mean APAC companies are increasingly held to FDA and EMA standards even when their local regulator hasnt asked.

The companies that treat Part 11 as a one-off project tend to struggle with it forever. The ones that build it into how they run their systems, day to day, tend to forget its even a regulation.

If youd like an honest assessment of where your systems stand, thats exactly the conversation we like having.

Get in touch with Valina Services for a Part 11 gap assessment or a tailored discussion about your compliance needs.

This blog provides general information and should not be considered regulatory advice. Always consult qualified professionals regarding your specific compliance requirements.

Posted by Dr Suhanya Parthasarathy, PhD | Valina Services Pte Ltd